CARE Ratings Q1 FY27: Revenue ₹111 Cr, PAT ₹33 Cr

What CARE Ratings reported for Q1 FY27

CARE Ratings Limited has announced its financial results for the first quarter of FY27 ended June 30, 2026. The company reported double-digit growth in both revenue and profit on a consolidated basis compared with the year-ago quarter. Consolidated revenue for the quarter came in at ₹111 crore, while consolidated net profit was ₹33 crore. The company attributed performance to traction across its rating and advisory services. The update was disclosed under SEBI Listing Regulations.

Consolidated performance: revenue up 18.21%, profit up 24.53%

For the quarter ended June 30, 2026, CARE Ratings reported consolidated revenue of ₹111 crore, up 18.21% year-on-year from ₹93.9 crore in the same quarter last year. Consolidated net profit rose to ₹33 crore from ₹26.5 crore, a year-on-year increase of 24.53%. The company also indicated the quarter’s revenue increased both sequentially and year-on-year to ₹111 crore, and that net profit increased versus the corresponding prior-year period. The reported numbers point to faster growth in profit than revenue for the quarter.

How this compares with Q1 FY26 operating metrics

The base quarter (Q1 FY26) had operating income of ₹93.9 crore. For the same period, EBITDA was reported at ₹27.8 crore and EBITDA margin at 30%. Profit after tax (PAT) in Q1 FY26 was ₹26.5 crore, with a PAT margin of 25%. EPS for Q1 FY26 stood at ₹8.61. These historical disclosures provide context to the year-on-year comparison embedded in the Q1 FY27 update.

Board meeting and regulatory disclosure details

CARE Ratings disclosed that its board meeting was scheduled for Friday, August 7, 2026. The primary agenda was to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY2027). The company stated the disclosure was made under SEBI Listing Regulations. Such board-meeting intimation is typically filed with stock exchanges as part of standard compliance.

Trading window closure under insider trading rules

The company also disclosed trading-window compliance under SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in company shares was closed effective July 1, 2026, as intimated on June 26, 2026. The closure will continue until 48 hours after the declaration of the financial results. This is a common measure to restrict trading by insiders during the period when unpublished price-sensitive information may exist.

Stock price snapshot and market indicators cited

As of July 6, 2026, CARE Ratings’ share price was cited at ₹1,674.7. Another price snapshot in the document lists CARE Ratings at ₹1,674.7 on NSE and ₹1,672.85 on BSE as on 6/7/2026. The same material also lists a “Price” of ₹1,726 and a market cap of about ₹5.4K crore, alongside a P/E of 31.6, and elsewhere notes a market cap of ₹5,410. The document also includes a separate “Current Price” entry of ₹1,600, indicating multiple market snapshots across different points.

What estimates were suggesting before the print

The material includes an external estimate from Uniresearch for Q1 FY27. Uniresearch projected revenue of ₹112 crore (+19.0% YoY) and PAT of ₹32 crore (+23.8% YoY), using Q1 FY26 as the base (revenue ₹94 crore, PAT ₹26 crore as cited in that estimate section). Against this estimate set, the company’s reported consolidated revenue of ₹111 crore was marginally lower than the ₹112 crore projection, while net profit of ₹33 crore was higher than the ₹32 crore projection. These comparisons are limited to what is explicitly stated in the provided text.

Full-year FY26 context: income, profit, and dividend

For the full year ended March 31, 2026, the company disclosed revenue from operations of ₹473.0705 crore, and total income of ₹527.8853 crore. Annual net profit for FY26 was ₹173.6959 crore, and basic EPS for FY26 was ₹57.06. The board also recommended a final dividend of ₹14 per equity share (face value ₹10) for the year ended March 31, 2026. Combined with an interim dividend of ₹8 per share paid in Q2 FY26, the total dividend for FY26 was ₹22 per share.

Key numbers table: Q1 FY27 vs Q1 FY26

Compliance and exchange filing trail

The disclosure references filings to BSE Limited and the National Stock Exchange of India. The text includes the BSE Corporate Relation Department address at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001, and the NSE Listing Department address at Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. It also provides the company’s address as 4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai 400 022.

Market performance table included in the material

The document also lists percentage price performance for CARE Ratings across different periods.

Why this quarter matters for investors tracking ratings agencies

The Q1 FY27 numbers extend the company’s pattern of year-on-year growth referenced in the material, with revenue and profit both rising in double digits versus the same period last year. The compliance disclosures around board approval, exchange intimation, and trading-window closure provide the procedural framework around the results release. The broader financial context for FY26, including total income of ₹527.8853 crore and net profit of ₹173.6959 crore, helps investors benchmark quarterly performance against the latest annual base. Beyond the reported figures and disclosures, the provided text does not include information on any order book or pending orders.

Conclusion

CARE Ratings reported consolidated revenue of ₹111 crore and consolidated net profit of ₹33 crore for Q1 FY27, marking 18.21% and 24.53% year-on-year growth, respectively. The company also flagged the August 7, 2026 board meeting for approval of unaudited results and reiterated trading-window closure timelines under insider trading regulations. Next, investors will track the formal declaration process and subsequent reopening of the trading window 48 hours after the results are declared.